<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433730</url>
  </required_header>
  <id_info>
    <org_study_id>22102014</org_study_id>
    <nct_id>NCT02433730</nct_id>
  </id_info>
  <brief_title>Testosterone Therapy in Hypogonadal Men Treated With Opioids</brief_title>
  <official_title>The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marianne Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of testosterone replacement therapy in&#xD;
      men with low testosterone due to opioid treatment on body composition, the haemostatic&#xD;
      system, glucose metabolism, muscle function, pain sensitivity, pain modulation, lipids,&#xD;
      sexual function and quality of life.&#xD;
&#xD;
      Male patients on opioids for non-malignant diseases aged 18-59 years diagnosed with&#xD;
      hypogonadotrophic hypogonadism, referred from day hospitals and outpatient populations. 40&#xD;
      patients are randomized to either testosterone undecanoate i.m. or placebo i.m., i.e. 20&#xD;
      patients per arm&#xD;
&#xD;
      A double blinded randomized placebo controlled trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is 24 weeks. Patients are treated with Testosterone Undecanoate 1000 mg/4&#xD;
      ml, intramuscular (i.m.) or placebo at 0, 6 and 18 weeks.&#xD;
&#xD;
      Outcome measures will be evaluated at 0 and 14 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lean body mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>dual xray absorptiometry scan</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>testosterone</arm_group_label>
    <other_name>nebido</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients 18-75 years&#xD;
&#xD;
          -  Treatment with opioid for &gt;3 months, daily dose &gt;50-100 mg&#xD;
&#xD;
          -  Total testosterone &lt; 12 mmol/L&#xD;
&#xD;
          -  Follicle Stimulating Hormone (FSH)/Luteinizing Hormone (LH) levels normal og below&#xD;
             normal laboratory values&#xD;
&#xD;
          -  Normal prolactin levels&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematocrit&gt; 54% at screening&#xD;
&#xD;
          -  Prostate Specific Antigen (PSA) &gt; 3 ng/ml&#xD;
&#xD;
          -  Severe organic and mental disease&#xD;
&#xD;
          -  current or present cancer diagnosis&#xD;
&#xD;
          -  Previous venous thrombotic embolism and cerebrovascular disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Epilepsy or migraine not adequately controlled by therapy&#xD;
&#xD;
          -  Severe benign prostate hypertrophy with symptom score &gt;19&#xD;
&#xD;
          -  Sleep apnea&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Implantation of sustained action sex hormone in the last 12 months&#xD;
&#xD;
          -  Use of oral, buccal or transdermal testosterone in the last two weeks&#xD;
&#xD;
          -  Treatment with glucocorticoids &gt; 5 mg/day or 5 alfa reductase inhibitors&#xD;
&#xD;
          -  Hypersensitivity to Nebido&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odensen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Andersen</investigator_full_name>
    <investigator_title>Professor, MD,</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

